About Seaport Therapeutics
Seaport Therapeutics is a company based in Boston (United States) founded in 2020 by Steven Paul and Daphne Zohar.. Seaport Therapeutics has raised $325 million across 2 funding rounds from investors including PureTech Health, T. Rowe Price and General Atlantic. Seaport Therapeutics offers products and services including Glyph Platform and SPT-320. Seaport Therapeutics operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Boston, United States
- Founders Steven Paul, Daphne Zohar
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$325 M (USD)
in 2 rounds
-
Latest Funding Round
$225 M (USD), Series B
Oct 18, 2024
-
Investors
PureTech Health
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Seaport Therapeutics
Seaport Therapeutics offers a comprehensive portfolio of products and services, including Glyph Platform and SPT-320. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables oral bioavailability and reduces side effects for drugs
Prodrug of Agomelatine for treating neuropsychiatric disorders
Funding Insights of Seaport Therapeutics
Seaport Therapeutics has successfully raised a total of $325M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $225 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $225.0M
-
First Round
First Round
(09 Apr 2024)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series B - Seaport Therapeutics | Valuation | General Atlantic , Foresite Capital | |
| Apr, 2024 | Amount | Series A - Seaport Therapeutics | Valuation | Arch Venture Partners , Sofinnova Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Seaport Therapeutics
Seaport Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include PureTech Health, T. Rowe Price and General Atlantic. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Seaport Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Seaport Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Seaport Therapeutics Comparisons
Competitors of Seaport Therapeutics
Seaport Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Seaport Therapeutics
When was Seaport Therapeutics founded?
Seaport Therapeutics was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Where is Seaport Therapeutics located?
Seaport Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Seaport Therapeutics?
Daphne Zohar is the current CEO of Seaport Therapeutics. They have also founded this company.
Is Seaport Therapeutics a funded company?
Seaport Therapeutics is a funded company, having raised a total of $325M across 2 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Apr 09, 2024.
What does Seaport Therapeutics do?
Seaport Therapeutics was founded in 2020 and is headquartered in Boston, United States. Focus is placed on the biotechnology sector, where a pipeline of neuropsychiatric medicines is advanced through the proprietary Glyph Technology. This approach utilizes the lymphatic system to enhance clinically validated mechanisms. Operations include development of SPT-300, an oral prodrug of allopregnanolone targeted at anxious depression.
Who are the top competitors of Seaport Therapeutics?
Seaport Therapeutics's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
What products or services does Seaport Therapeutics offer?
Seaport Therapeutics offers Glyph Platform and SPT-320.
Who are Seaport Therapeutics's investors?
Seaport Therapeutics has 8 investors. Key investors include PureTech Health, T. Rowe Price, General Atlantic, Arch Venture Partners, and Foresite Capital.